19 Aug
  • By Greg Freeman
  • Cause in

There’s No Straight Line in Drug Development

Today’s FDA disapproval of Sarepta’s Vyondys 53 is disheartening, but a true example of just how difficult and costly the drug development process is.  We appreciate Sarepta’s efforts and dedication to helping those with Duchenne and are confident that Doug Ingram and his team will not let this slow them down. In drug development there […]

READ MORE
28 Jun
  • By Greg Freeman
  • Cause in

Summary of Pfizer Phase 1 Microdystrophin Gene Therapy Trial

Pfizer made their first public disclosure on early data from their open-label Phase 1 microdystrophin gene therapy trial for the treatment of Duchenne. The program was obtained from Pfizer’s acquisition of Bamboo Therapeutics, a Cure Duchenne funded company. Pfizer’s preliminary data is very encouraging despite two SAE’s which resolved with approved treatment. We are eager […]

READ MORE
25 Jun
  • By Sha
  • Cause in

Updates on CureDuchenne Gene Therapy Initiative

We are excited to report the progress of CureDuchenne’s Gene Therapy Initiative.  From our investment, as early as 2010, in Nationwide Children’s permanent duplication2 skipping program, to what has become Pfizer’s Duchenne gene therapy trial, to founding the first Duchenne gene editing company, Exonics (recently acquired by Vertex), to investing in crucial AAV manufacturing in […]

READ MORE
14 Feb
  • By Jessica Yanez-Perez
  • Cause in

The Phase 3 PolarisDMD Trial Goes Global

With a flurry of recent activity, 17 trial sites are now open for enrollment. We are especially excited to share that our first international sites in Canada and Australia have launched. Sites are also expected to launch soon in Europe and Israel.

READ MORE
13 Feb
  • By Jessica Yanez-Perez
  • Cause in

UT Southwestern Wellstone Symposium

We are excited about the UT Southwestern Wellstone Symposium on March 30!  Don’t forget to RSVP by March 1.  We’ll see you there! 

READ MORE
06 Feb
  • By CureDuchenne User
  • Cause in

NS Pharma Community Letter

We are excited that our industry partner, NS Pharma, has applied for accelertated approval for it’s exon 53 skipping therapy, viltolarsen. We applaud the dedication to the Duchenne community by NS Pharma and look forward to continued success. NS Pharma Community Letter

READ MORE